124 related articles for article (PubMed ID: 18021966)
1. Variability in donor-specific alloantibody production after transplantation.
Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
Transplant Proc; 2007 Nov; 39(9):2715-7. PubMed ID: 18021966
[TBL] [Abstract][Full Text] [Related]
2. Alloantibodies and the outcome of cadaver kidney allografts.
Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
[TBL] [Abstract][Full Text] [Related]
3. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
4. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
5. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
6. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
[TBL] [Abstract][Full Text] [Related]
7. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
Cardarelli F; Pascual M; Tolkoff-Rubin N; Delmonico FL; Wong W; Schoenfeld DA; Zhang H; Cosimi AB; Saidman SL
Transpl Int; 2005 May; 18(5):532-40. PubMed ID: 15819801
[TBL] [Abstract][Full Text] [Related]
9. Blood group Lewis alloantibodies cause antibody-mediated rejection in renal transplant recipients.
Boratyńska M; Banasik M; Hałoń A; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2711-4. PubMed ID: 18021965
[TBL] [Abstract][Full Text] [Related]
10. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Mazanowska O; Krajewska M; Zabińska M; Bartoszek D; Myszka M; Nowakowska B; Dawiskiba T; Lepiesza A; Chudoba P; Klinger M
Transplant Proc; 2013 May; 45(4):1449-52. PubMed ID: 23726594
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?
Gupta A; Iveson V; Varagunam M; Bodger S; Sinnott P; Thuraisingham RC
Transplantation; 2008 Apr; 85(8):1200-4. PubMed ID: 18431242
[TBL] [Abstract][Full Text] [Related]
12. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.
Lachmann N; Terasaki PI; Schönemann C
Clin Transpl; 2006; ():171-99. PubMed ID: 18365377
[TBL] [Abstract][Full Text] [Related]
13. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
Aubert V; Venetz JP; Pantaleo G; Pascual M
Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
[TBL] [Abstract][Full Text] [Related]
14. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
15. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
16. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.
Seveso M; Bosio E; Ancona E; Cozzi E
Contrib Nephrol; 2009; 162():87-98. PubMed ID: 19001816
[TBL] [Abstract][Full Text] [Related]
17. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
[TBL] [Abstract][Full Text] [Related]
19. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients.
Wahrmann M; Bartel G; Exner M; Regele H; Körmöczi GF; Fischer GF; Böhmig GA
Transpl Int; 2009 Oct; 22(10):982-9. PubMed ID: 19619171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]